NOSTIFIX 0.5 mg price in UAE

Overview

Welcome to Dwaey, specifically on NOSTIFIX 0.5 mg Tablet page.
This medicine contains an important and useful components, as it consists of Cabergoline.
NOSTIFIX 0.5 mg is available in the market in concentration 0.5 mg/Tablet and in the form of Tablet .

JAZEERA PHARMACEUTICAL INDUSTRIES is the producer of NOSTIFIX 0.5 mg and it is imported from SAUDI ARABIA, The most popular alternatives of NOSTIFIX 0.5 mg are listed downward .

Mode Of Action

Cabergoline is a long-acting dopamine D2-agonist. It inhibits prolactin secretion through hypothalamic inhibitory control exerted through the release of dopamine.

Indication

Hyperprolactinemia
prolactinomas
parkinson's disease
uterine fibroids
acromegaly
cushing's disease
pituitary adenomas
lactation suppression

Precaution

CV disease, Raynaud's syndrome, renal or hepatic impairment, peptic ulcer, GI bleeding, history of psychosis, hypertension. May affect ability to drive or operate machinery. Pregnancy, lactation. Prolonged use and/or usage of high doses may lead to psychiatric disorders, pleural/retroperitoneal fibrosis or cardiac valvular fibrosis. Monitor serum prolactin level mthly until normalisation. Monitor hepatic function regularly in patients with hepatic impairment. Lactation: excretion in milk unknown; use with caution

Side Effects

>10% Nausea (27%)
Headache (26%)
Dizziness (15%)
Constipation (10%) 1-10% Asthenia (9%)
Fatigue (7%)
Abdominal pain (5%)
Somnolence (5%)
Postural hypotension (4%)
Depression (3%)
Dyspepsia (2%)
Nervousness (2%)
Abnormal vision (1%)
Breast pain (1%)
Dysmenorrhea (1%)
Hot flashes (1%)
Paresthesia (1%) Potentially Fatal: Risk of serotinin syndrome with sibutramine; avoid combination.

Contra indication

Hypersensitivity to ergot derivatives. Uncontrolled hypertension.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Increased risk of orthostatic hypotension when used with antihypertensives. May increase vasoconstriction effect of dopamine. May reduce vasodilation effect of nitroglycerin. Concurrent use with SSRIs or TCAs may increase the risk of serotonin syndrome. Potentially Fatal: Risk of serotonin syndrome with sibutramine.